AnteoTech (ASX: ADO) Drops 14% on $3.5m Raise – Buy the Dip or Avoid the Dilution?

AnteoTech Slides on $3.5m Raise as Dilution Fears Hit

AnteoTech (ASX: ADO) dropped 14.2 per cent on Tuesday to A$0.018 after announcing a A$3.5 million capital raise at a steep discount. The company will issue 245.69 million new shares at A$0.0155 each, plus 122.8 million options as a sweetener for investors. That price sits 26 per cent below the last traded price, which spooked short-term holders.

But here’s the thing: the selloff may be missing the bigger picture. AnteoTech now has two clear paths to growth, EV batteries and medical diagnostics, and both are gaining real traction. With analysts still pointing to a target of A$0.38 (roughly 20 times the current price), the gap between market price and perceived value has rarely been wider.

What are the Best ASX Tech Stocks to invest in right now?

Check our buy/sell tips

AnteoTech Targets EV and Diagnostics Markets With Fresh Capital

AnteoTech makes special coatings and materials. In simple terms, they help batteries last longer, and medical tests work better.

On the battery side, the company’s Ultranode technology uses silicon instead of graphite in battery anodes. Silicon stores more energy, which means longer-lasting batteries and faster charging. The company has already proven this works; Ultranode has hit more than 1,000 charge cycles at 80 per cent capacity, the gold standard for EV batteries.

More importantly, Mercedes-Benz is testing this technology right now. The German carmaker placed its first commercial order back in late 2024, and management is now negotiating a strategic EV partnership, potentially building on that Mercedes-Benz relationship.

On the medical side, AnteoTech’s AnteoBind NXT technology helps diagnostic tests detect diseases faster and more accurately. The Serum Institute of India, one of the world’s biggest vaccine makers, just placed a US$185,000 order that shipped in early January 2026. They’re also testing a new ELISA plate prototype, which could open the door to a US$21 billion global market.

Why the Recent Selloff Could Create Opportunity

The 14 per cent drop looks painful, but context matters. AnteoTech’s Life Sciences revenue grew around 130 per cent in FY2025 to approximately A$930,000. That’s still small, but the direction is clear.

The company also has solid non-dilutive funding to lean on. A A$4 million ARENA grant supports battery development through 2027, and a A$2.6 million R&D tax rebate landed in August 2025. These grants reduce the need for future capital raises and give management room to execute.

Yes, the placement adds dilution. But the cash extends the runway and funds the sales push needed to convert partnerships into revenue.

The Investor’s Takeaway for ADO

The bull case: AnteoTech offers rare dual exposure to two booming sectors, EV batteries and medical diagnostics. The Mercedes-Benz relationship adds credibility, while Serum Institute’s repeat orders show the Life Sciences business is gaining real customers. If either division lands a major partnership, the stock could re-rate quickly.

The bear case: This is still a pre-revenue-scale company burning cash. The placement dilutes existing shareholders by around 9 per cent, and there’s no guarantee that Mercedes-Benz testing leads to a production deal. Execution risk remains high.

Our view: For investors who can stomach volatility, the current price looks interesting. The key catalyst to watch is any announcement on an expanded Mercedes-Benz partnership, which alone could shift market perception overnight.